Advertisement

Boehringer Ingelheim Corp., a pharmaceutical firm in Ridgefield, Conn., has returned positive antiviral activity results from a Phase 2 clinical trial of its hepatitis C virus (HCV) treatment, BI 201335.

The treatment, a once-daily oral protease inhibitor, showed improvements in both chronic genotype-1 HCV patients with a history of multiple treatments, as well as those new to HCV treatment. The protease inhibitor was tested in conjunction with patients receiving current standard of care, including pegylated interferon and ribavirin.

SOURCE

Advertisement
Advertisement